Jefferies Assumes Fate Therapeutics (FATE) at Buy, 'We Predict (+) NK Data in May, More at ASCO'
Tweet Send to a Friend
Jefferies analyst Michael Yee assumes coverage on Fate Therapeutics (NASDAQ: FATE) with a Buy rating and a price target of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
